Figure 3 | Scientific Reports

Figure 3

From: PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model

Figure 3

Kaplan–Meier survival curves for OS and PFS according to PD-L1 expression. PD-L1 expression values were classified as high expression (≥ 7.65) or low expression (< 7.65). (A) The OS curves for all patients (n = 126). The OS (B) and PFS (C) curves for the ASCT group (n = 33) are shown. The OS (D) and PFS (E) curves for the non-ASCT group (n = 126), including 93 patients who did not receive ASCT and 33 patients censored at the time of ASCT. Besides, the OS (F) and PFS (G) curves for the subgroups of patients (n = 53) who received frontline VTD, TD, or RD therapy that included IMiD are shown in this figure. The OS (H) and PFS (I) curves are for the subgroups of patients who did not receive IMiD therapy (n = 73). ASCT autologous stem cell transplantation, IMiD immunomodulatory drug, OS overall survival, PFS progression-free survival, RD lenalidomide-dexamethasone, TD thalidomide-dexamethasone, VMP bortezomib-melphalan-prednisolone, VTD bortezomib-thalidomide-dexamethasone.

Back to article page